AMGN

SEC source: 0000318154-26-000025 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 501,862

F1 · balance_after: These shares include 2,696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000026 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,292

F1 · balance_after: These shares include 825 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000027 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,267

F1 · balance_after: These shares include 659 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000028 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,001

F1 · balance_after: These shares include 756 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000029 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,488

F1 · balance_after: These shares include 122 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000030 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,291

F1 · balance_after: These shares include 120 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000031 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,173

F1 · balance_after: These shares include 197 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000032 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,787

F1 · balance_after: These shares include 744 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000033 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,404

F1 · balance_after: These shares include 696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000023 · form4.xml · derivative · entry 5

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 119,782 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000023 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 492,643

F2 · balance_after: These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000023 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 576,928

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Non-market exercise of a total of 119,872 stock options expiring May 3, 2026 wherein 84,285 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.

SEC source: 0000318154-26-000013 · form4.xml · nonDerivative · entry 1

Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,361

F1 · balance_after: These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000014 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 457,146

F1 · balance_after: These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000015 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,807

F1 · balance_after: These shares include 740 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000016 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,478

F1 · balance_after: These shares include 590 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000017 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,587

F1 · balance_after: These shares include 676 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000018 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,249

F1 · balance_after: These shares include 110 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000019 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,972

F1 · balance_after: These shares include 107 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000020 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,744

F1 · balance_after: These shares include 176 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000021 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,650

F1 · balance_after: These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000022 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,877

F1 · balance_after: These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000012 · form4.xml · derivative · entry 7

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,291 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000012 · form4.xml · derivative · entry 6

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,501 shares

Expires 2027-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000012 · form4.xml · nonDerivative · entry 4

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,618

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2 · price: The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer

F3 · balance_after: These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000012 · form4.xml · nonDerivative · entry 3

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000012 · form4.xml · nonDerivative · entry 2

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,618

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2 · price: The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer

SEC source: 0000318154-26-000012 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000011 · form4.xml · nonDerivative · entry 1

Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,423

F1 · balance_after: These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000006 · form4.xml · nonDerivative · entry 2

Bradner James E. · CIK 0002005159 · EVP, Research and Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,378

F1 · balance_after: These shares include 1,205 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000006 · form4.xml · nonDerivative · entry 1

Bradner James E. · CIK 0002005159 · EVP, Research and Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,331

SEC source: 0000318154-25-000083 · form4.xml · derivative · entry 7

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,639 shares

Expires 2027-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000083 · form4.xml · derivative · entry 6

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,970

Underlying: Common Stock · 1,500 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 4

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,225

F1 · price: The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 3

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,225

F1 · price: The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000080 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,503

F2 · kind: The transaction reported involved a gift by the reporting person of shares of the Company's common stock to a non-profit charitable organization.

F3 · balance_after: These shares include 583 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000081 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,923

F1 · price: The price reported is an average price. The prices ranged from $336.7301 to $337.0500 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000082 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,082

F1 · price: The price reported is an average price. The prices ranged from $336.2219 to $336.30 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000080 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,812

F1 · kind: The transaction reported involved a gift by the reporting person of shares of the Company's common stock to a charitable donor advised fund.

SEC source: 0000318154-25-000077 · form4.xml · nonDerivative · entry 1

Drake Michael V · CIK 0001938942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,958.6425

F1 · balance_after: These shares include 268 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000078 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,834.085

F1 · balance_after: These shares include 1,393 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000079 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,507.5436

F1 · balance_after: These shares include 338 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000075 · form4.xml · nonDerivative · entry 1

Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,414

F1 · balance_after: These shares include 51 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000076 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,972

F1 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000062 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,209

F1 · balance_after: These shares include 80 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000060 · form4.xml · nonDerivative · entry 1

Drake Michael V · CIK 0001938942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,699.0291

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 227 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000061 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,241.9302

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 291 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-020372 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,469.6259

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 1,294 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.